Posted 21st March 2018 by Anna Gomez
Precision medicine in oncology requires matching each patient with treatment personalised to their genes and often the proteomic profile of their cancer. Liquid biopsies continue to gain grounds as a tool for diagnostic testing in oncology.
Posted 13th March 2018 by Kate Barlow
The pharmaceutical research industry is suffering from a lack of innovation, yet we see an exponential increase in new science and technologies. Open innovation, in the truest meaning, is a disruptive model that will greatly increase our joint chances of translating new research into treatments, but we need new ways of sharing and participating in collaborative drug research. Blockchain technologies can provide the digital infrastructure that allows trusted and secure transactions of research assets. Applying smart contracts on top of such infrastructure will further increase the speed of the life science ecosystem allowing exploration, co-creation, and transaction of research assets to happen in an unprecedented manner. In fact, we can’t afford to object to such a marriage between pharma open innovation and blockchain technologies.
Posted 7th February 2018 by Kate Barlow
What is the blockchain?
According to a recent Forbes article: the blockchain is one of the most misunderstood technologies of 2017 (1). While most healthcare professionals have heard the term “blockchain” and are aware of the innovations in financial technology, few understand the fundamental principles behind the technology in order to speculate the impacts it will have on the healthcare industry, at hospitals, and for patients. This inability is common across sectors and can be attributed to the absence of any standard definition of blockchain technology. However, it is important that industry leaders have a firm basis for understanding it in order to foresee its impacts on their business. What follows is a list of key points for understanding the blockchain and enabling speculation on its impacts in healthcare:
Posted 31st January 2018 by Kate Barlow
This article was originally published on the Surrey CoDE blog in January 2018, and is published here with permission.
Posted 20th September 2017 by Laura Berry
Over the past five years, e-Therapeutics have created a drug discovery engine based on a combination of large-scale, proprietary databases and a suite of computational tools. Small molecules are evaluated by their potential bioactivity in the search for better and more effective drugs to address unmet medical needs. This article outlines the core principles and advantages of the Network-Driven Drug Discovery (NDD) approach.
Posted 13th February 2017 by Laura Berry
Organic Light Emitting Diodes (OLEDs)
Organic Light Emitting Diodes (OLEDs) are sub-micrometric devices formed by multi-stacked materials that have reached the appropriate Technological Readiness Level to be present in displays. Intense research has permitted the construction of diodes with long lifetimes, multi-colour emission and size variety.